CELL & GENE THERAPY
DEVELOPMENT

7-8 JULY 2020 - ONLINE EVENT

Online Event

BUILDING THE FUTURE OF CELL AND GENE THERAPY DEVELOPMENT POST COVID-19



SPONSORS:

topathermal

Miltenyi Biotec

PALL Biotech

Cell & Gene Therapy Development
Online Event

WELCOME

Here at Pharma iQ we know the value of community and connections - they are what our whole business is built upon. Whilst the current global environment is challenging, we remain comitted to supporting you by finding ways to bring the industry together, encourage engagement and promote discussion.

We are therefore delighted to announce that our inaugural Cell and Gene Therapy Webinar will take place from 7-8 July. This online forum focuses on those innovative, industry-leading companies who are pivoting their process development and manufacturing strategies to drive clinical development and sustain regulatory compliance for cell and gene therapies.

Discussions will cover the end-to-end development lifecycle, with a particular focus on how the current climate of uncertainty is forcing positive change and flexibility for the industry. This first of its kind webinar will share expert guidance, solutions, and strategies to help you adapt your role and processes, and to ensure that you overcome the challenges of right now to accelerate clinical development, foster an agile business culture and - ultimately - continue developing your life saving therapies.

IT'S GOOD TO TALK

In times like these it's reassuring to have others to talk to, benchmark against and to share your experiences and concerns. That's why we have created the **Cell and Gene Therapy Development Webinar**, to bring communities together to learn from one another, discuss the impact of 2020, and find ways forward in this time of unprecedented disruption and change.

Cell & Gene Therapy Development
Online Event

WHY JOIN US?

The webinar provides an opportunity to come together with the community, and learn from experts who will share their recent experiences

Learn from Pluristem Therapeutics as they outline how to build an agile platform for Allogenic development under Covid-19

Map the transition towards a decentralised manufacturing strategy with ADVA Bio's best practice guidance

Discover the changing nature of research translation under Covid-19 with UCL's update on their process adjustments and priorities

Learn from real life adaptation and process management use-cases from the likes of Bone Therapeutics and Novo Nordisk to ensure your company will come out ahead from Covid-19



Cell & Gene Therapy Development
Online Webinar

SPEAKER FACULTY

Miguel Forte
CEO
Bone Therapeutics

Ohad Karnieli
CEO
ADVA Biotechnology

Anthony Davies
CEO
Dark Horse

Pernille Linnert Jensen
Senior Scientist and Project Leader Stem Cell R&D
Novo Nordisk

Louisa Mathias
Group Lead, Process Development and Manufacturing
GammaDelta Therapeutics

Rob Allen
Director
Dark Horse

Matthew Cobb
Clinical Account Manager
Miltenyi Biotech

Lior Raviv
VP Development and Operations
Pluristem Therapeutics

Pamela Tranter
Head of Translation
UCL

Paul Cashen
Senior Bioprocess Specialist
Pall Biotech

Cell & Gene Therapy Development Online Event

WHO'S INVITED

We will bring together a community of ATMP industry experts from senior management, director, VP levels and above across the industries leading cell and gene therapy companies. Our network spans autologous, allogenic and gene therapy specialist manufacturers, giving us a holistic industry platform.

Invitations for attendance will be sent to our highly engaged community of Pharma and Biotech clients, alongside expert industry solution providers.

Previous attending accounts include:

Johnson & Johnson, Novartis, Air Liquide Healthcare, Miltenyi Biotec, Pluristem, Amgen, solvias, STEMCELL Technologies, gsk, GammaDelta Therapeutics, Bone Therapeutics, immatics, DHC Dark Horse Consulting, GE Healthcare, Kite A Gilead Company, novo nordisk, BLUECRUX, aldevron The basis for breakthroughs, MHRA, Adva Biotechnology, UCL

Pharma iQ

8,200

Pharma/Biotech Professionals

Industry Expert Job Functions Include:

- Manufacturing
- Product development
- Production
- Technical
- Process Scientist
- GMP Manufacturing
- Quality Assurance
- Process development
- Regulatory Compliance
- CEO, CMO, COO



Cell & Gene Therapy Development
Online Webinar

AGENDA - 7 JULY

CELL & GENE THERAPY DEVELOPMENT

10:15 BST Pharma iQ Welcome

10:20 BST Chairman's Opening Remarks

10:30 BST Cell and Gene Therapy Under Covid-19

- Map the impact of Covid 19 across the Cell and Gene Industry and ascertain key areas of impact
- Discuss the emergent challenges and opportunities in light of Covid-19 for CTG development and commercialisation
- Analyse lessons learned in the past 4 months and how the industry can use this situation to better prepare for the future

Anthony Davies, CEO, **Dark Horse**

11:15 BST Optimising Cell Process of MCS's to Enhance ARDS and SARS-CoV-2 Specific T-cell Generation

- Examine use cases demonstrate the versatility of the CliniMACS Prodigy® Platform in processing of MCS's

Matthew Cobb, Clinical Account Manager, **Miltenyi Biotech**,

12:00 BST Building an Agile Operational Platform for Allogeneic Cell Therapies Under Covid-19

- Hear how Pluristem have adjusted their operational platform from pre-Covid-19 to now and what they have done to increase platform adaptation and flexibility
- Discuss building a flexible operational framework for allogeneic delivery in Israel and beyond
- Examine ways in which Pluristem were able to adjust their logistical framework and supply networks to increase speed of response and decrease time to patient

Lior Raviv, VP Development and Operations, **Pluristem Therapeutics**,

Cell & Gene Therapy Development
Online Event

AGENDA - 7 JULY

CELL & GENE THERAPY DEVELOPMENT

12:45 BST Lunch Break

14:00 BST An End-to-End Integrated Solutions approach to Commercial Viral Vector Manufacturing

Paul Cashen, Senior Bioprocess Specialist**, Pall Biotech**

14:45 BST Panel Discussion: Strategies to Maintain Development and Minimise Timeline Delays Under Covid-19

- Identify opportunities to adapt your manufacturing and process development strategies to accommodate for the current climate
- Debate the challenges present for materials management and sourcing with border closures and social distancing
- Examine company strategies to minimise clinical and commercialization disruptions
- Discuss key lessons learned under Covid-19 and what it may mean for industry development

Louisa Mathias, Group Lead, Process Development and Manufacturing, **GammaDelta Therapeutics**
Matthew Cobb, Clinical Account Manager**, Miltenyi Biotech**

15:45 BST Close of Day 1

Cell & Gene Therapy Development
Online Event

AGENDA – 8 JULY

10:20 BST Chairman's Welcome and Summary of Day 1

10:30 BST Transitioning Towards a Decentralised Manufacturing Strategy

- Discuss how - and why - ADVA ave proactively moved from a centralised to decentralised manufacturing strategy
- Examine how decentralised manufacturing can alleviate the challenges posed by closing borders and ongoing flight cancellations
- Weigh up the costs of goods with the benefits of transitioning towards decentralisation with reference to logistics management, regulatory approval and speed of supply
- Identify critical elements to enable decentralized manufacturing

Ohad Karnieli, CEO, **ADVA Bio**,

11:15 BST *Session Reserved for Sponsor*

12:00 BST Looking at the Research Perspective: Translation under Covid-19 at UCL

- Outline the biggest challenges presented to UCL's translational model when identifying high potential candidates
- Discuss the role of academic research and translation in addressing the current pandemic environment, and the challenges inherent with timeline management
- Analyse how changes in industry priorities and broader governmental support an be used to maximise the relationship between the academic and private sectors tofast-track viable therapies into development

Pamela Tranter, Head of Translational Research Group - Cell and Gene Therapy, **UCL**

Cell & Gene Therapy Development
Online Event

AGENDA – 8 JULY

CELL & GENE THERAPY DEVELOPMENT

12:45 BST Lunch Break

14:00 BST Maintaining a C&GT Biotech through the COVID-19 Crisis: Challenges and Opportunities

- Engage with the bone Therapeutics perspective on the changes to clinical development for allogenic cell therapies under Covid-19
- Discuss strategies to re-enforce your clinical operations to mitigate against delays and maintain development consistency

Miguel Forte, CEO, **Bone Therapeutics**

14:45 BST *Session Reserved for Sponsor*

15:30 BST Case Study: Stem Cell Raw Materials Qualification at Novo Nordisk

- How to balance safety, compliance and speed when qualifying raw materials for very different stem cell therapy purposes like cell banking or drug product manufacture for Clinical Phase I/II, Phase III or the Market

Pernille Linnert Jensen, Senior Scientist and Project Leader Stem Cell R&D**, Novo Nordisk**

16:15 BST *Chairman's Closing Summar and End of Webinar*

Cell & Gene Therapy Development
Online Event

HOW TO REGISTER

CELL & GENE THERAPY
DEVELOPMENT
7-8 JULY 2020

Pass Includes

- Webinar Day 1 & 2 (7th - 8th July)
- Access to Post Event Presentations
- Access to Event Networking App

Pharma and Biotech Product Manufacturers - **FREE**

Solutions Providers : **Early Bird Price - 299***
(**Register before Friday 5th June)*
Standard Price - 499

The process:

- Emailing us to confirm your place at **team@iqpc.co.uk**
- **Register online here**

Want to Sponsor? Get in touch!

Get in touch with our expert team to discuss your objectives and brand story for a full marketing consultation

To learn more, please get in touch today:
Gal Cohen - Business Development Manager
e: **partner@iqpc.co.uk**
t: **+44 207 368 9300**